-
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Friday, May 31, 2019 - 12:45pm | 1570Read More...The FDA approval machinery worked overtime in May, with several new labelings, original approvals and new molecule approvals coming through in the month. The month saw the approval of two new molecular entities, or NMEs: Novartis AG (NYSE: NVS)'s Piqray in combination with fulvestrant to treat...
-
What To Make Of Alexion's New FDA Approval
Tuesday, October 24, 2017 - 8:10am | 421Read More...Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) were trading higher by more than 5 percent early Tuesday morning after the U.S. Food and Drug Administration approved its therapy called Soliris (eculizumab) for the treatment of adults with generalized myasthenia gravis (gMG). GMG represents a...
-
Alexion Shares Under Pressure Amid Brazilian Office Raid; Barclays Says Buy The Dip
Tuesday, May 9, 2017 - 8:12am | 331Read More...Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a biopharmaceutical company perhaps most known for its Soliris therapy fell more than 3 percent during Monday's trading session. Investors and traders were reacting to a Bloomberg report, which said Alexion's offices in Brazil were raided by...
-
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Monday, March 20, 2017 - 8:17am | 1119Read More...In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...
-
Alexion's Drug Trial Miss Doesn't Change Analysts' Long-Term Thesis
Thursday, December 22, 2016 - 11:15am | 342Read More...Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced that Soliris has failed to meet primary endpoints in a Phase II/III study related to the prevention of delayed graft function in adult recipients of diseased-donor kidney transplants who have elevated risk of disease. Soliris failed to achieve...
-
Shkreli's Very Bullish Call On Alexion Following Recent Downside: 'Double From Here'
Tuesday, November 15, 2016 - 2:29pm | 346Read More...Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), which saw a move above the $130 handle in the aftermath of its financial results released on October 27, have lost some of the sheen now. Alexion's third-quarter results showed that the company reversed to a profit of $0.42 per share...
-
Despite Alexion's Internal Investigation, Goldman Standing Behind Its Buy Rating
Thursday, November 10, 2016 - 2:08pm | 412Read More...Goldman Sachs stuck to its Buy rating on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), which delayed filing of its third-quarter report as it is under investigation regarding its sales practices of lead drug Soliris based on the allegations of a former employee. The Investigation Soliris is...
-
Alexion Management On Internal Investigation: So Far, So Good
Thursday, November 10, 2016 - 11:04am | 285Read More...Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced on November 9 that its 10Q filing would be delayed due to the ongoing investigation into the company’s sales practices. Credit Suisse’s Alethia Young maintains an Outperform rating on the company with a price target of $165. Delayed...
-
How Wedbush Sees The Alexion–Synageva Deal
Thursday, May 7, 2015 - 8:42am | 300Read More...In a report published Wednesday, Wedbush analyst David Nierengarten, Ph.D. commented on the merger agreement whereby Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) will acquire Synageva Biorpharma Corp (NASDAQ: GEVA) for $115 per share in cash and 0.6581 Alexion shares – valuing shares of Synageva at...
-
Market Wrap For May 5: Dow Erases Triple-Digit Loss, All Three Major Indices Positive
Monday, May 5, 2014 - 3:36pm | 2443Read More...U.S. stocks rose as investors found that the positives in the U.S. services sector outweighed concerns over an escalating conflict in Ukraine. The Institute for Supply Management said that its service-sector index rose to 55.2. Any reading above 50.0 indicates an expansion. Also, the index...
-
Barron's Recap (3/24/12): Profiles of the World's Best CEOs
Sunday, March 25, 2012 - 10:16am | 941Read More...This weekend in Barron's online: the annual listing of the top 30 corporate chiefs, a look at Deere, International Game Technology and Alexion Pharmaceuticals, as well as growth in Latin American airlines. Cover Story “World's Best CEOs” by Andrew Bary. Barron's offers up its annual listing of...
